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Background. In Bihar, India, home to nearly one-half of the world’s burden of visceral leishmaniasis, drug
resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although
monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase
efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the
feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated
Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course
oral miltefosine.
Methods. We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 sub-
jects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine
for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by
miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45
additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days
(group E).
Results. Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses.
Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%–
97%]; group B, 98% (95% CI, 87%–100%); group C, 96% (95% CI, 84%–99%]; group D, 96% (95% CI, 84%–
99%); and group E, 98% (95% CI, 87%–100%).
Conclusions. These results suggest that treatment with single-dose L-AmB followed by 7–14 days of miltefosine
is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and
in those regions of endemicity where visceral leishmaniasis may be more difficult to treat.
Trial registration. ClinicalTrials.gov identifier: NCT00370825.
Efforts to improve the treatment of visceral leishman-
iasis (also known as kala-azar) and develop new ther-
apeutic approaches have moved steadily forward in the
past decade. This progress has been driven, in part, by
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the emergence of large-scale resistance to conventional
pentavalent antimony (Sb) treatment in Bihar, India,
which accounts for ∼90% of India’s (and ∼45% of the
world’s) cases of kala-azar [1, 2]. Recent therapeutic
advances in Indian kala-azar include demonstration of
the efficacy of short-course treatment using the lipid
formulations of amphotericin B [3], identification of
miltefosine as the first effective oral agent [4], and re-
discovery of paromomycin [5].
In parallel with the development of new single-drug
regimens, there is also growing interest in resurrecting
the notion of combination therapy to treat visceral
leishmaniasis, as practiced, for example, in the treat-
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ment of tuberculosis, HIV infection, and malaria. Such an ap-
proach, in the form of Sb plus aminosidine (paromomycin),
was tested initially in Kenya, India, and Sudan in the 1990s
and enhanced overall efficacy and/or reduced treatment du-
ration [6–8]. Combination Sb-paromomycin therapy is cur-
rently in use in Sudan [9]. Other potential advantages of 2-
drug chemotherapy in the treatment of kala-azar include: (1)
less toxicity (as a result of lower drug doses and/or shorter
treatment courses); (2) convenience, better compliance, and
lower costs, resulting from less lengthy treatment; and (3) pos-
sibly reduced likelihood of developing resistance to either agent.
In view of the fate of Sb in Bihar [1], there is also understand-
able concern about how to best preserve the efficacy of new
single-agent treatments that are now being deployed, especially
in regions of endemicity, such as India, where transmission is
anthroponotic [2,10].
Using 2 self-administered oral drugs would be ideal in kala-
azar; however, only 1 drug, miltefosine (Impavido; Zentaris),
is currently available [2, 4]. Therefore, in considering what
might constitute optimal combination therapy in Bihar, where
Sb is not an option, we focused this pilot trial on testing the
particularly active parenteral agent liposomal amphotericin B
(L-AmB), which is marketed under the brand name AmBisome
(Gilead Sciences), with short-course miltefosine. In devising
the test regimens, we took advantage of 2 prior findings in the
same Indian population: (1) a single infusion of L-AmB by
itself at 7.5 or 5 mg/kg can induce cure rates of 90%–91% [11,
12], and (2) although miltefosine is ordinarily given for 28 days
[4], limited data suggest reasonable activity (89% cure rate)
with a 14-day course [13]. Thus, if used in combination (in
this case, sequentially), reducing the duration of miltefosine
treatment and/or lowering the dose of L-AmB both appeared
to be feasible.
PATIENTS AND METHODS
This study, carried out from August 2006 through March 2007
at the Kala-Azar Medical Research Center in Muzaffarpur, Bi-
har, India, was approved by the Center’s ethical committee and
registered with ClinicalTrials.gov (identifier: NCT00370825).
Trial design. This trial was designed as a randomized, par-
allel-arm, noncomparative, open-label study using a group-
sequential (triangular test) method to reach—with the mini-
mum number of subjects—an early decision as to which
regimens should be selected for additional testing. Of note, in
a classic single-stage comparative trial design with a type 1 error
a of 5%, a power of 95%, and the null hypothesis of1 b
90% efficacy, a sample size of 580 patients per arm would be
needed to reach the significance level for a regimen with 95%
efficacy.
The study was designed to have a 5% type 1 error and 95%
power ( and ), considering a failure rate ofap .05 ßp .05
!10% to indicate adequate efficacy (the minimum detectable
failure rate at the level) and a failure rate 25% toßp .05
indicate insufficient efficacy. The boundaries of the test were
calculated for H0 ( ) and Ha ( ) withpp p0 p ! pa p0p 0.25
and . Based on simulations, we expected the samplepap 0.10
path to cross the H0 rejection line with an average sample size
of 40 patients and the H0 non-rejection line with an average
sample size between 20 and 25 patients. When, after enrolling
45–46 patients per arm, all treatments appeared to be equally
and highly effective, an additional 45 consecutive patients were
enrolled and nonrandomly assigned to a fifth regimen.
Eligibility and entry and exclusion criteria. Patients 12
years of age were eligible for the study if they had symptoms
and signs of kala-azar (e.g., fever, weight loss, and splenomeg-
aly) and parasites demonstrated by microscopic examination
of splenic aspirate smear [4, 5]. Pregnant or breast-feeding
women and individuals who were seropositive for HIV or who
had a serious concurrent infection, such as tuberculosis or bac-
terial pneumonia, were excluded. Exclusion criteria also in-
cluded granulocyte count !1000 cells/mL, hemoglobin level!3.5
g/dL or platelet count !40,000 platelets/mL, hepatic transami-
nase levels or total bilirubin 13 times the upper limit of normal,
serum creatinine level 12.0 mg/dL, and prothrombin time 15
sec above control. If they were randomized to receive milte-
fosine, women of child-bearing age with negative pregnancy
test results were counseled about the potential teratogenic ef-
fects of miltefosine and were offered contraception in the form
of a depot preparation of progesterone. All such women en-
rolled in this study gave consent and received the injection.
Trial procedures and treatments. Subjects completed base-
line testing (including standard biochemistry and hematology
profiles, urinalysis, examination of chest radiographs, electro-
cardiogram, anti-HIV antibody testing by ELISA, malaria
smear, and pregnancy testing) and provided written informed
consent. An independent statistician generated a randomization
schedule by use of a computer-based procedure; assumptions
were a maximum number of 60 patients enrolled per arm (240
total patients) and 15 randomization blocks with a size of 15
patients each. Sealed randomization envelopes were prepared,
and treatment was begun within 72 h after diagnosis by splenic
aspirate. All subjects received L-AmB once on day 1 as a 2-h
intravenous infusion [11, 12]; antipyretic pretreatment was not
used. Miltefosine was started on day 2 and was administered
at 100 mg per day (50 mg twice-daily with meals) [4]. Drugs
were generously donated by Gilead Sciences (L-AmB) and Zen-
taris (miltefosine); neither manufacturer had a role in the plan-
ning, conduct, or analysis of the study or in the preparation
and publication of this article.
Initially, 181 subjects were randomly assigned according to
a group-sequential (triangular) design to receive either 5 mg/
kg of L-AmB administered once (group A), 5 mg/kg of L-AmB
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administered once plus miltefosine for either 10 days (group
B) or 14 days (group C), or 3.75 mg/kg of L-AmB administered
once plus miltefosine for 14 days (group D). After initial post-
treatment assessments on day 16 showed apparent cure re-
sponses in all 181 subjects, the protocol was amended to include
a fifth group of 45 subjects (group E) with use of the same
inclusion and exclusion criteria. These nonrandomized subjects
received 5 mg/kg of L-AmB administered once followed by
miltefosine for 7 days.
Patients were kept in our inpatient unit throughout treat-
ment and were examined daily. Complete blood counts and
serum creatinine and hepatic transaminase levels were obtained
on day 8 and day 16 or when warranted clinically; limited
resources precluded additional laboratory testing. On day 8,
miltefosine treatment was to be withheld if the creatinine level
doubled from baseline and exceeded 2.0 mg/dL or if any value
exceeded 2.5 mg/dL; miltefosine treatment was not to be re-
started until the level decreased to 1.4 mg/dL, the upper limit
of normal. Adverse events were also classified according to the
Common Toxicity Criteria as mild (grade 1), moderate (grade
2), severe (grade 3), or very severe (grade 4) [4, 5]. Treatment
was to be discontinued and subjects removed from the study
if adverse events of Common Toxicity Criteria grade 3 oc-
curred, with the exception of increases in liver transaminase
levels. Such increases may occur during miltefosine therapy,
but they do not preclude continuing treatment [4].
Splenic aspirate for apparent cure evaluation was repeated
on day 16. For groups A, B, C, D, and E, day 16 represented
15, 5, 1, 1, and 8 days, respectively, since the last treatment
dose. Parasite density score for pretreatment and posttreatment
splenic aspirate smears was graded by microscopic examination
in a blinded fashion with use of a conventional logarithmic
scale of 0 (indicating no parasites per 1000 oil-immersion fields)
to +6 (indicating 1100 amastigotes per field) [4, 5]. Designation
of apparent cure on day 16 required clinical improvement, a
reduction in spleen size, and a splenic aspirate score of 0 (i.e.,
apparent parasitological cure) [4, 5]. Definitive cure, assessed
after 9 months, required being healthy with no signs or symp-
toms of relapse [4, 5]. All subjects were given 400 rupees (US
$9) to offset the costs of travel to the 9-month visit. Patients
who did not return on time were contacted in person. No
subject was lost to follow-up.
Statistical analysis. For continuous variables, data are ex-
pressed as mean value (SE). Frequencies are given as per-
centages with 95% CIs. Pretreatment (baseline) characteristics
were compared between groups to determine any imbalances
by using a 1-way analysis of variance. Continuous data were
assessed for normality using the Kolmogorov-Smirnov test. If
statistically significant, data were log-transformed and analyzed
using the Student’s t test, if normally distributed; the Mann-
Whitney U test was used for paired comparisons. Homogeneity
of variance was assessed with the Bartlett test. The Welch ad-
justed analysis of variance was performed if variances were
unequal. Dichotomous variables were analyzed using the x2 test.
In the design of the trial, cure rate at day 16 was considered
to be the primary end point and, for the purposes of this study,
was used as a surrogate for cure rate at month 9. The day 16
cure rate was analyzed for every 5 subjects in each noncom-
parative arm using the triangular test.
Secondary parameters were also considered for comparisons
between day 0 and day 16. Normally distributed differences
between baseline and day 16 were analyzed with a paired Stu-
dent’s t test. Non–normally distributed data, assessed by the
Kolmogorov-Smirnov test, were analyzed by the Wilcoxon
signed rank-sum test. All tests were 2-tailed except the trian-
gular test. A P value of !.05 was considered to be statistically
significant. Data were analyzed using SAS, version 9.1.3 (SAS
Institute).
RESULTS
Figure 1 summarizes the trial profile and table 1 shows baseline
clinical and laboratory results. Twenty-two subjects (10%) had
received prior treatment, 19 with Sb, in equal proportions
across all groups. At baseline, patients in the 5 groups were
similar except for higher WBC counts ( ) and plateletPp .04
counts ( ) in groups C, D, and E than in groups A andP ! .001
B. Clinically severe kala-azar (i.e., spleen size 18 cm and he-
moglobin level !7.0 g/dL [14]) was present in 1–4 patients in
each of groups A–D and in none of the patients in group E.
All 181 subjects in groups A–D completed assigned treat-
ments with no drug interruptions, and on day 16, 100% had
parasite-free splenic aspirate smears and fulfilled the criteria
for apparent cure (tables 1 and 2). Because of identical initial
responses, 45 additional subjects (group E) were enrolled and
treated with 5 mg/kg of L-AmB administered once followed by
an abbreviated (7-day) course of miltefosine. All group E pa-
tients completed treatment, and all 45 patients were also ap-
parently cured at the day 16 assessment. Additional posttreat-
ment results indicated significant decreases in spleen size and
increases in weight, hemoglobin levels, and WBC and platelet
counts in each patient group (comparing values at day 16 vs.
baseline values; table 1).
Higher temperature, rigors, or both responses developed
during L-AmB infusion in 9–13 subjects (20%–29%) in each
of the 5 groups. These anticipated infusion-related reactions
[11, 12, 15] were transient, and single-dose L-AmB treatment
was considered to be well-tolerated. Posttreatment (day 16)
results for each group also showed no meaningful change in
serum creatinine levels nor, with the exception of group C, in
hepatic transaminase levels (table 1).
Adverse events in individual patients are shown in table 3,
in which day 8 corresponds to 1 week after treatment with L-
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Figure 1. Trial profile for a new treatment approach in Indian visceral leishmaniasis using single-dose liposomal amphotericin B (L-AmB) followed
by short-course oral miltefosine.
AmB alone (group A), end of treatment in group E, three-
quarters through treatment in group B, and halfway through
treatment for groups C and D. Similarly, day 16 represents the
following posttreatment intervals: group A, 15 days; group B,
6 days; group E, 8 days; and in groups C and D, the day
treatment ended. Vomiting and diarrhea during the first week
of therapy and increases in serum creatinine and serum glu-
tamic pyruvic transaminase levels were anticipated in milte-
fosine-treated patients [4]; however, these reactions also oc-
curred in several individuals who received L-AmB alone. In
general, adverse events were mild (grade 1) or moderate (grade
2) and, in most instances, resolved or improved to grade 1 by
day 16. However, 3 group C subjects developed Common Tox-
icity Criteria grade 3 (severe) hepatotoxicity (which resolved
during continued miltefosine treatment), and a fourth patient
experienced an asymptomatic grade 4 reaction (very severe)
with a serum glutamic pyruvic transaminase level that reached
3425 IU/mL. When retested 2 weeks after treatment, this sub-
ject’s serum glutamic pyruvic transaminase value had returned
to normal.
During the 9-month posttreatment period, 1 group A patient
died during a flood 5 months after treatment (table 2). In
addition, 9 patients developed symptomatic, parasitologically
confirmed relapses (7 during months 1–6 and 2 during months
7–9). All 216 remaining patients were asymptomatic and ap-
peared to be healthy at month 9 and were judged to have shown
a definitive cure response. Thus, overall cure rates, by intention-
to-treat analysis, were as follows: group A, 91% (95% CI, 78%–
97%); group B, 98% (95% CI, 87%–100%); group C, 96%
(95% CI, 84%–99%); group D, 96% (95% CI, 84%–99%); and
group E, 98% (95% CI, 87%–100%). The 9 patients who ex-
perienced relapse were retreated successfully using full-dose L-
AmB therapy (15 mg/kg total dose, administered at a dosage
of 3 mg/kg/day for 5 days) [15].
DISCUSSION
In India, kala-azar is conventionally treated with a single agent.
Although Sb has now been lost as a viable treatment option in
Bihar because of the development of drug resistance [1, 15],
alternative therapies have emerged and are effective, although
they are not without certain drawbacks [2, 15]. For example,
intravenous treatment with amphotericin B deoxycholate usu-
ally requires 30 days in the hospital and may be difficult to
tolerate [14]; a 5-day course of intravenous L-AmB (e.g., total
dose of 15 mg/kg [15, 16]) is expensive despite its newly dis-
counted price (US $20 per 50-mg vial); a 28-day course of oral
miltefosine remains fairly expensive, even at the discounted
price offered to the World Health Organization (US $84 for a
patient weighing 125 kg), although drug cost is largely offset
by savings from outpatient self-administration [17]; and, al-
though inexpensive, paromomycin requires 21 days of daily
intramuscular injections [5].
Therefore, in the preceding context and versus monotherapy,
the use of 2 active antileishmanial drugs with distinct mech-
anisms of action may have potential advantages, such as en-
hanced overall efficacy, the ability to maintain high-level cure
rates when using either lower drug doses or shorter treatment
periods, less drug-related toxicity, and the possibility of limiting
the emergence of resistance to either agent. The possibility of
emerging drug resistance has already been raised for miltefosine
[18].
The results of this pilot study indicate the feasibility of a
particular approach to combination treatment in Indian kala-
azar that takes advantage of the effectiveness of single-dose L-
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Table 2. Responses to treatment for patients treated for Indian visceral leishmaniasis using single-dose
liposomal amphotericin B (L-AmB) followed by short-course oral miltefosine.
Variable Group A Group B Group C Group D Group E
L-AmB dose, mg/kg 5 5 5 3.75 5
Duration of miltefosine treatment, days 0 10 14 14 7
Enrolled 45 46 45 45 45
Completed treatment 45 46 45 45 45
Apparent cure on day 16 45 46 45 45 45
Relapse 3 1 2 2 1
Death 1 0 0 0 0
Lost to follow-up 0 0 0 0 0
Definitive cure at 9 monthsa 41 45 43 43 44
Percentage of patients with definitive cure
at 9 monthsa (95% CI) 91 (78–97) 98 (87–100) 96 (84–99) 96 (84–99) 98 (87–100)
NOTE. Data are no. of patients, unless otherwise indicated. Group A received 5 mg/kg of L-AmB administered once. Group B
received 5 mg/kg of L-AmB administered once plus miltefosine for 10 days. Group C received 5 mg/kg of L-AmB administered once
plus miltefosine for 14 days. Group D received 3.75 mg/kg of L-AmB administered once plus miltefosine for 14 days. Group E
received 5 mg/kg of L-AmB administered once plus miltefosine for 7 days. All subjects received a single infusion of the indicated
dose of L-AmB on day 1.
a Patients who experienced relapse (np 9) or died (np 1) by month 9 were designated as having experienced treatment failure.
Table 3. Adverse clinical and laboratory reactions among patients treated for Indian visceral leishmaniasis
using single-dose liposomal amphotericin B (L-AmB) followed by short-course oral miltefosine.
Reaction
Group A
(n p 45)
Group B
(n p 46)
Group C
(n p 45)
Group D
(n p 45)
Group E
(n p 45)
Day 8 Day 16 Day 8 Day 16 Day 8 Day 16 Day 8 Day 16 Day 8 Day 16
Vomiting
Grade 1 0 0 0 0 0 0 0 0 0 0
Grade 2 5 0 9 0 5 0 6 0 1 0
Diarrhea
Grade 1 3 0 6 0 4 0 4 0 2 0
Grade 2 0 0 2 0 3 0 1 0 0 0
Creatinine level
Grade 1 0 3 12 5 4 4 4 3 5 0
Grade 2 0 0 2 0 0 0 0 0 2 0
SGPT level
Grade 1 13 10 12 9 15 8 15 10 18 10
Grade 2 1 0 2 2 0 0 3 1 1 0
Grade 3 0 0 0 0 3 0 0 0 0 0
Grade 4 0 0 0 0 0 1 0 0 0 0
NOTE. Group A received 5 mg/kg of L-AmB administered once. Group B received 5 mg/kg of L-AmB administered once plus
miltefosine for 10 days. Group C received 5 mg/kg of L-AmB administered once plus miltefosine for 14 days. Group D received
3.75 mg/kg of L-AmB administered once plus miltefosine for 14 days. Group E received 5 mg/kg of L-AmB administered once plus
miltefosine for 7 days. All subjects received a single infusion of the indicated dose of L-AmB on day 1. In groups B–E, miltefosine
was started on day 2 and given for the indicated periods. For clinical reactions, results (Common Toxicity Criteria grade) indicate
the number of patients in whom reactions developed during days 1–8 (day 8) or days 9–16 (day 16). Laboratory results show the
numbers of patients in whom the indicated reactions were present on either day 8 or 16. SGPT, serum glutamic pyruvic transaminase.
AmB [11, 12] and the efficacy and convenience of oral mil-
tefosine [4, 17]. Our findings suggest that the use of these 2
agents in tandem may permit a new short-course approach,
potentially allowing the duration of miltefosine therapy and the
amount of L-AmB administered to be reduced. Both effects
may help mitigate the cost of using 2 expensive drugs. (The
estimated drug cost in India for a 40-kg patient in group E,
for example, would be US $101.) Our results also suggest that
sequential treatment with these 2 agents is satisfactorily tol-
erated and, as judged by initial and long-term responses, does
not interfere in any meaningful fashion with either parasito-
logical or clinical efficacy. As with any miltefosine-containing
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regimen, this form of treatment is contraindicated in pregnant
women; in addition, women of child-bearing age need to main-
tain effective contraception during and for 2 months after treat-
ment [4].
It is important to note that this trial was designed to identify
suitable options for combination treatment deserving further
study and to discard less active regimens. The study was ran-
domized to avoid selection biases when enrolling patients, al-
though a fifth group (group E) was added when it became clear
that all 4 of the regimens that were initially tested were ap-
parently effective. This trial was noncomparative and was not
designed (nor was it of sufficient size) to address other relevant
questions. These include: (1) whether the addition of milte-
fosine meaningfully improves upon the ∼90% cure rate of treat-
ment with single-dose L-AmB alone [11, 12]; (2) whether any
of the tested combination regimens are as effective as giving
miltefosine alone for 28 days (which has a 94% cure rate for
hospitalized subjects and protocol-adherent outpatients [4, 17]
and an 84% cure rate for all outpatients [17]); and (3) what
is the proper dose of L-AmB and proper duration of miltefosine
treatment to use in tandem? Future studies will be needed to
address such questions.
Nevertheless, although they are preliminary, our results do
suggest the possibilities of using L-AmB at !5 mg/kg (e.g., at
3.75 mg/kg, as in group D) as well as oral therapy in courses
as short as 7–10 days (as in groups E and B). If this particular
combination approach to kala-azar in Bihar is supported by
additional trials aimed at inducing a cure rate of 195% [14,
19], 1 infusion of L-AmB (in most instances, administered in
an outpatient setting) followed by a brief self-administered
course of miltefosine would be a regimen with clear-cut clinical
appeal.
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